Todorović-Raković, N

Link to this page

Authority KeyName Variants
b86c2c98-a7d5-4d54-9924-9bfa49d993c4
  • Todorović-Raković, N (2)
Projects

Author's Bibliography

Elevated plasma levels of transforming growth factor-beta(1) (TGF-beta(1)) in patients with advanced breast cancer: association with disease progression

Ivanović, Vesna; Todorović-Raković, N; Demajo, Miroslav; Nešković-Konstantinović, Zora; Subota, Vesna; Ivanišević-Milovanović, Olivera; Nikolić-Vukosavljević, Dragica

(2003)

TY  - JOUR
AU  - Ivanović, Vesna
AU  - Todorović-Raković, N
AU  - Demajo, Miroslav
AU  - Nešković-Konstantinović, Zora
AU  - Subota, Vesna
AU  - Ivanišević-Milovanović, Olivera
AU  - Nikolić-Vukosavljević, Dragica
PY  - 2003
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2617
AB  - We examined the association between an elevated plasma TGF-beta(1) level and the disease progression of advanced breast cancer (BC) patients (n = 44). TGF-beta(1) levels were detected by an enzyme-linked immunosorbent assay (ELISA). Platelet carryover and in vitro platelet activation in our plasma samples was assessed and found to be insignificant. Plasma TGF-beta(1) values were significantly elevated (P LT 0.05) in stage IIIB/IV patients (median value: 2.40 ng/ml, range: 0.13-8.48 ng/ml, n=44) compared with healthy donors (median value: 1.30 ng/ml, range: 0.41-4.93 ng/ml, n=36). Although pronounced in metastatic patients, especially those who had been newly diagnosed, TGF- and beta;(1) elevation was independent of tumour mass, site of distant metastases, histopathological type, steroid receptor (SR) content and age of the BC patients. Follow-up of 6 patients indicated a relationship between the plasma TGF- and beta;(1) and the patients response. This suggests that TGF- and beta;(1), may be a promising prognostic marker for breast cancer patients with advanced disease. Confirmatory large-scale studies are needed, particularly given the overlap of values between our different subgroups analysed.
T2  - European Journal of Cancer
T1  - Elevated plasma levels of transforming growth factor-beta(1) (TGF-beta(1)) in patients with advanced breast cancer: association with disease progression
VL  - 39
IS  - 4
SP  - 454
EP  - 461
DO  - 10.1016/S0959-8049(02)00502-6
ER  - 
@article{
author = "Ivanović, Vesna and Todorović-Raković, N and Demajo, Miroslav and Nešković-Konstantinović, Zora and Subota, Vesna and Ivanišević-Milovanović, Olivera and Nikolić-Vukosavljević, Dragica",
year = "2003",
abstract = "We examined the association between an elevated plasma TGF-beta(1) level and the disease progression of advanced breast cancer (BC) patients (n = 44). TGF-beta(1) levels were detected by an enzyme-linked immunosorbent assay (ELISA). Platelet carryover and in vitro platelet activation in our plasma samples was assessed and found to be insignificant. Plasma TGF-beta(1) values were significantly elevated (P LT 0.05) in stage IIIB/IV patients (median value: 2.40 ng/ml, range: 0.13-8.48 ng/ml, n=44) compared with healthy donors (median value: 1.30 ng/ml, range: 0.41-4.93 ng/ml, n=36). Although pronounced in metastatic patients, especially those who had been newly diagnosed, TGF- and beta;(1) elevation was independent of tumour mass, site of distant metastases, histopathological type, steroid receptor (SR) content and age of the BC patients. Follow-up of 6 patients indicated a relationship between the plasma TGF- and beta;(1) and the patients response. This suggests that TGF- and beta;(1), may be a promising prognostic marker for breast cancer patients with advanced disease. Confirmatory large-scale studies are needed, particularly given the overlap of values between our different subgroups analysed.",
journal = "European Journal of Cancer",
title = "Elevated plasma levels of transforming growth factor-beta(1) (TGF-beta(1)) in patients with advanced breast cancer: association with disease progression",
volume = "39",
number = "4",
pages = "454-461",
doi = "10.1016/S0959-8049(02)00502-6"
}
Ivanović, V., Todorović-Raković, N., Demajo, M., Nešković-Konstantinović, Z., Subota, V., Ivanišević-Milovanović, O.,& Nikolić-Vukosavljević, D.. (2003). Elevated plasma levels of transforming growth factor-beta(1) (TGF-beta(1)) in patients with advanced breast cancer: association with disease progression. in European Journal of Cancer, 39(4), 454-461.
https://doi.org/10.1016/S0959-8049(02)00502-6
Ivanović V, Todorović-Raković N, Demajo M, Nešković-Konstantinović Z, Subota V, Ivanišević-Milovanović O, Nikolić-Vukosavljević D. Elevated plasma levels of transforming growth factor-beta(1) (TGF-beta(1)) in patients with advanced breast cancer: association with disease progression. in European Journal of Cancer. 2003;39(4):454-461.
doi:10.1016/S0959-8049(02)00502-6 .
Ivanović, Vesna, Todorović-Raković, N, Demajo, Miroslav, Nešković-Konstantinović, Zora, Subota, Vesna, Ivanišević-Milovanović, Olivera, Nikolić-Vukosavljević, Dragica, "Elevated plasma levels of transforming growth factor-beta(1) (TGF-beta(1)) in patients with advanced breast cancer: association with disease progression" in European Journal of Cancer, 39, no. 4 (2003):454-461,
https://doi.org/10.1016/S0959-8049(02)00502-6 . .
123
102
127

Detection of transforming growth factor-beta 1 in human plasma - A pilot study on breast cancer patients

Ivanović, Vesna; Todorović-Raković, N; Demajo, Miroslav; Nešković-Konstantinović, Zora; Nikolić-Vukosavljević, Dragica; Ivanišević-Milovanović, Olivera; Mitrovic, L

(2001)

TY  - JOUR
AU  - Ivanović, Vesna
AU  - Todorović-Raković, N
AU  - Demajo, Miroslav
AU  - Nešković-Konstantinović, Zora
AU  - Nikolić-Vukosavljević, Dragica
AU  - Ivanišević-Milovanović, Olivera
AU  - Mitrovic, L
PY  - 2001
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2438
AB  - There has been much controversy concerning the detection of plasma TGF-beta (1) levels in breast cancer patients. The present study provides preliminary evidence on underestimated plasma TGF-beta (1) levels due to ex vivo proteolysis and previous therapeutic treatment of breast cancer patients, as detected by a commercial ELISA immunoassay. Our results revealed that the addition of protease inhibitors: phenylmethylsulfonyl fluoride and aprotinin, to the plasma preparation of healthy volunteers, has increased TGF-beta (1) median Value from 3.1 ng/mL to 33.9 ng/mL. Relative to that, in protease-inhibited plasma of locally advanced/metastatic breast cancer patients, significantly elevated TGF-beta (1) was observed (median value: 65.5 ng/mL), which included untreated and previously treated patients with median values of: 74.2 ng/mL and 58.1 ng/mL, respectively. These findings indicate to the potential usefulness of this plasma marker in breast cancer prognosis, thus deserving future clinical attention.
T2  - Jugoslovenska Medicinska Biohemija
T1  - Detection of transforming growth factor-beta 1 in human plasma - A pilot study on breast cancer patients
VL  - 20
IS  - 2
SP  - 81
EP  - 87
UR  - https://hdl.handle.net/21.15107/rcub_vinar_2438
ER  - 
@article{
author = "Ivanović, Vesna and Todorović-Raković, N and Demajo, Miroslav and Nešković-Konstantinović, Zora and Nikolić-Vukosavljević, Dragica and Ivanišević-Milovanović, Olivera and Mitrovic, L",
year = "2001",
abstract = "There has been much controversy concerning the detection of plasma TGF-beta (1) levels in breast cancer patients. The present study provides preliminary evidence on underestimated plasma TGF-beta (1) levels due to ex vivo proteolysis and previous therapeutic treatment of breast cancer patients, as detected by a commercial ELISA immunoassay. Our results revealed that the addition of protease inhibitors: phenylmethylsulfonyl fluoride and aprotinin, to the plasma preparation of healthy volunteers, has increased TGF-beta (1) median Value from 3.1 ng/mL to 33.9 ng/mL. Relative to that, in protease-inhibited plasma of locally advanced/metastatic breast cancer patients, significantly elevated TGF-beta (1) was observed (median value: 65.5 ng/mL), which included untreated and previously treated patients with median values of: 74.2 ng/mL and 58.1 ng/mL, respectively. These findings indicate to the potential usefulness of this plasma marker in breast cancer prognosis, thus deserving future clinical attention.",
journal = "Jugoslovenska Medicinska Biohemija",
title = "Detection of transforming growth factor-beta 1 in human plasma - A pilot study on breast cancer patients",
volume = "20",
number = "2",
pages = "81-87",
url = "https://hdl.handle.net/21.15107/rcub_vinar_2438"
}
Ivanović, V., Todorović-Raković, N., Demajo, M., Nešković-Konstantinović, Z., Nikolić-Vukosavljević, D., Ivanišević-Milovanović, O.,& Mitrovic, L.. (2001). Detection of transforming growth factor-beta 1 in human plasma - A pilot study on breast cancer patients. in Jugoslovenska Medicinska Biohemija, 20(2), 81-87.
https://hdl.handle.net/21.15107/rcub_vinar_2438
Ivanović V, Todorović-Raković N, Demajo M, Nešković-Konstantinović Z, Nikolić-Vukosavljević D, Ivanišević-Milovanović O, Mitrovic L. Detection of transforming growth factor-beta 1 in human plasma - A pilot study on breast cancer patients. in Jugoslovenska Medicinska Biohemija. 2001;20(2):81-87.
https://hdl.handle.net/21.15107/rcub_vinar_2438 .
Ivanović, Vesna, Todorović-Raković, N, Demajo, Miroslav, Nešković-Konstantinović, Zora, Nikolić-Vukosavljević, Dragica, Ivanišević-Milovanović, Olivera, Mitrovic, L, "Detection of transforming growth factor-beta 1 in human plasma - A pilot study on breast cancer patients" in Jugoslovenska Medicinska Biohemija, 20, no. 2 (2001):81-87,
https://hdl.handle.net/21.15107/rcub_vinar_2438 .
2